Missense Mutant Patatin‐Like Phospholipase Domain Containing 3 Alters Lipid Droplet Turnover in Partnership With CGI‐58
Scott McHenry, Nicholas O. Davidson – 22 March 2019
Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis
Banishree Saha, David Tornai, Karen Kodys, Adeyinka Adejumo, Patrick Lowe, Craig McClain, Mack Mitchell, Arthur McCullough, Srinivasan Dasarathy, Aimee Kroll‐Desrosiers, Bruce Barton, Svetlana Radaeva, Gyongyi Szabo – 19 March 2019 – Although mortality due to acute alcoholic hepatitis (AH) correlates with Model for End‐Stage Liver Disease (MELD) scores, biomarkers are critically needed to manage this disease. Increases in inflammatory markers and macrophage activation are associated with acute AH and could be potential biomarkers of clinical events and/or mortality.
Medication‐Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention
Kelly L. Hayward, Preya J. Patel, Patricia C. Valery, Leigh U. Horsfall, Catherine Y. Li, Penny L. Wright, Caroline J. Tallis, Katherine A. Stuart, Katharine M. Irvine, W. Neil Cottrell, Jennifer H. Martin, Elizabeth E. Powell – 18 March 2019 – People with decompensated cirrhosis are often prescribed a complex regimen of therapeutic and prophylactic medications. In other chronic diseases, polypharmacy increases the risk of medication misadventure and medication‐related problems (MRPs), with associated increased morbidity, mortality, and health care costs.
Underestimation of Liver Transplantation for Alcoholic Hepatitis in the National Transplant Database
Brian P. Lee, Gene Y. Im, John P. Rice, Ethan Weinberg, Christine Hsu, Oren K. Fix, George Therapondos, Hyosun Han, David W. Victor, Sheila Eswaran, Haripriya Maddur, Norah A. Terrault – 18 March 2019 – Alcohol‐associated liver disease (ALD) can be coded in United Network for Organ Sharing (UNOS) as either alcoholic cirrhosis or alcoholic hepatitis (AH), without having specific criteria to assign either diagnosis.
Vascular Remodeling of Visceral Arteries Following Interruption of the Splenic Artery During Liver Transplantation
Damiano Patrono, Eloisa Franchi, Fabio Guarasci, Germana Bartoli, Elisabetta Nada, Federica Rigo, Antonio Ottobrelli, Paolo Fonio, Mauro Salizzoni, Renato Romagnoli – 18 March 2019 – Splenic artery (SA) ligation can be performed during liver transplantation (LT) to avoid portal hyperperfusion, which is involved in the pathogenesis of both small‐for‐size and SA syndrome. The SA can also be used as an inflow for arterial reconstruction.
The Range and Reproducibility of the Liver Frailty Index
Connie W. Wang, Adrienne Lebsack, Stephanie Chau, Jennifer C. Lai – 18 March 2019 – The Liver Frailty Index (LFI), composed of 3 performance‐based tests (grip strength, chair stands, and balance), is a tool specifically developed in patients with cirrhosis to objectively measure physical function, a critical determinant of health outcomes.
Letter to the Editor: Will Vitamin E Be the Hope of Patients With NASH and Advanced Fibrosis? The Reliability Is Worth Discussing
Jian He, Ai‐Min Leng – 18 March 2019
Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis
Narendra S. Choudhary, Sanjiv Saigal, Neeraj Saraf, Arvinder S. Soin – 18 March 2019
Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct‐Acting Antiviral Treatment Failure in Patients With Hepatitis C?
Felix Piecha, Jan‐Michael Gänßler, Sabine Jordan, Can Ergen, Harald Ittrich, Johannes Kluwe, Sven Pischke, Ansgar W. Lohse, Julian Schulze zur Wiesch – 18 March 2019 – Direct‐acting antiviral (DAA) therapies have revolutionized the treatment of chronic hepatitis C virus infection, achieving sustained virological response (SVR) rates of >90% even in patients with advanced liver cirrhosis.